

Correspondence

Reporting of Systematic Reviews: The Challenge of Genetic Association Studies

Muin J. Khoury, Julian Little, Julian Higgins, John P. A. Ioannidis, Marta Gwinn

We applaud PLoS editors for their commitment to publishing high-quality systematic reviews (SRs) [1]. Moher et al. [2] clearly documented the inconsistent quality of reporting of SRs. With more than 2,500 SRs published every year, low-quality or outdated reviews may mislead researchers, providers, and policy makers. The situation could be improved if more evidence-based reporting guidelines were agreed upon, developed, and adhered to.

The growing field of genetic associations (GAs) illustrates the urgent need for transparent SRs and meta-analyses. Already, thousands of articles on GAs have been published, and the application of high-throughput genotyping methods may exponentially increase the number of reported associations [3]. Selective reporting of large numbers of false-positive associations could undermine the field and interfere with our ability to translate advances in genomics into clinical practice.

To address these problems, the Human Genome Epidemiology Network (HuGENet) was started as a global collaboration to strengthen methods of analysis and reporting of GAs and to develop a reliable knowledge base on the association between genetic variation and human diseases [4]. Between 2001 and 2006, the HuGENet online database assembled more than 25,000 published articles on GAs and more than 500 systematic reviews of GAs. Nevertheless, there are large inconsistencies in the quality of genetic association studies [5] and in the reporting of SRs of such associations [6]. In collaboration with several journals, HuGENet promotes the publication of transparently reported SRs of gene–disease associations [4]. More than 50 HuGE reviews have been published over the past six years.

After several HuGENet workshops bringing together researchers from different fields and journal editors, the first edition of a HuGENet handbook, modeled in part after the Cochrane handbook of systematic reviews, was published on the Canadian HuGENet Web site [7]. The handbook describes methodological issues and outlines steps in conducting such reviews, including the need for a detailed protocol. It also discusses meta-analysis methods. We strongly encourage researchers interested in conducting systematic reviews of GAs to consult the HuGENet handbook, and adopt transparent protocols. Retrospective SRs of published data have limitations, even when properly conducted. Investigators can advance the field of human genome epidemiology by conducting prospective meta-analyses and large collaborative analyses through international consortia. HuGENet has created a Network of Investigator Networks to help the growth of such initiatives [8]. ■

Muin J. Khoury (muk1@cdc.gov)

Marta Gwinn

Centers for Disease Control and Prevention
Atlanta, Georgia, United States of America

Julian Little

University of Ottawa
Ottawa, Ontario, Canada

Julian Higgins

Institute of Public Health
Cambridge, United Kingdom

John P. A. Ioannidis

University of Ioannina School of Medicine
Ioannina, Greece

References

1. The *PLoS Medicine* Editors (2007) Many reviews are systematic but some are more transparent and completely reported than others. *PLoS Med* 4: e147. doi:10.1371/journal.pmed.0040147
2. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG (2007) Epidemiology and reporting characteristics of systematic reviews. *PLoS Med* 4: e78. doi: 10.1371/journal.pmed.0040078
3. Khoury MJ, Little J, Gwinn M, Ioannidis JP (2006) On the synthesis and interpretation of consistent but weak gene-disease associations in the era of genome-wide association studies. *Int J Epidemiol*. E-pub 20 December 2006.
4. Centers for Disease Control and Prevention (2007) Human Genome Epidemiology Network (HuGENet). Available: <http://www.cdc.gov/genomics/hugenet/default.htm>. Accessed 24 May 2007.
5. Bogardus ST Jr, Concato J, Feinstein AR (1999) Clinical epidemiological quality in molecular genetic research: The need for methodological standards. *JAMA* 281: 1919–1926.
6. Attia J, Thakkinian A, D'Este C (2003) Meta analysis of molecular association studies: Methodologic lessons for genetic epidemiology. *J Clin Epidemiol* 56: 297–303.
7. Little J, Higgins J, editors (2006) The HuGENet HuGE review handbook, version 1.0. Available: http://www.genesens.net/_intranet/doc_nouvelles/HuGE%20Review%20Handbook%20v11.pdf. Accessed 24 May 2007.
8. Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, et al. (2006) A road map for efficient and reliable human genome epidemiology. *Nat Genet* 38: 3–5.

Citation: Khoury MJ, Little J, Higgins J, Ioannidis JPA, Gwinn M (2007) Reporting of Systematic Reviews: The challenge of genetic association studies. *PLoS Med* 4(6): e211. doi:10.1371/journal.pmed.0040211

Copyright: This is an open-access article distributed under the terms of the Creative Commons Public Domain Declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

Funding: The authors received no specific funding for this article.

Competing Interests: The authors have declared that no competing interests exist.

Reporting of Systematic Reviews: Better Software Required

Jan Brogger

This is an important paper and editorial [1,2]. Systematic reviews should be much more widespread, and not only for randomized clinical trials of clinical treatments. A paper on an elegant piece of experimental data or on epidemiological observations would be made all the more interesting if the first table were a high-quality assessment of previous studies. In fact, I would suggest that performing a systematic review should be part of a research protocol for any subject, even before the study is initiated. However, this paper confirms my suspicion that the rising popularity of “systematic reviews” has not been followed by adherence to methodological rigor.

With this background, I would like to point out one weakness that may explain part of the current quality deficit in some systematic reviews. There is a substantial lack of software that can assist in an important part of a systematic review: tracking literature searches and early phase screening. From

browsing of the literature and communications with various Norwegian and Danish Cochrane collaborators (including the RevMan developers), there seems to be a limited number of tools for this use. Oftentimes, it is suggested that commercial reference management software be used, such as the popular EndNote. These types of software were not designed with systematic reviews in mind. At later stages of a review, Cochrane's RevMan is useful, but not early on.

As far as I have been able to ascertain, there are only two tools presently available. The first is EPPI-Reviewer (<http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=184>), which is non-profit, but does not seem to be open source or available for local deployment. The second is TrialStat's SRS software (<http://www.trialstat.com>), which is commercial and has a substantial price tag.

I would therefore encourage researchers and institutions to contribute to the development of open-source tools for assisting in systematic reviews. I am currently writing such a simple tool, based on the open-source JabRef package (<http://sourceforge.net/projects/jabref>) and would welcome feedback on perceived needs and other similar projects. ■

Jan Brogger (jan.brogger@nevro.uib.no)

University of Bergen
Bergen, Norway

References

1. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG (2007) Epidemiology and reporting characteristics of systematic reviews. *PLoS Med* 4: e78. doi: 10.1371/journal.pmed.0040078
2. The *PLoS Medicine* Editors (2007) Many reviews are systematic but some are more transparent and completely reported than others. *PLoS Med* 4: e147. doi:10.1371/journal.pmed.0040147

Citation: Brogger J (2007) Reporting of Systematic Reviews: Better software required. *PLoS Med* 4(6): e225. doi:10.1371/journal.pmed.0040225

Copyright: © 2007 Jan Brogger. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The author received no specific funding for this article.

Competing Interests: The author has declared that no competing interests exist.

Neuraminidase Antibodies and H5N1: Geographic-Dependent Influenza Epidemiology Could Determine Cross-Protection against Emerging Strains

Jesus F. Bermejo-Martin, David J. Kelvin, Yi Guan, Honglin Chen, Pilar Perez-Breña, Inmaculada Casas, Eduardo Arranz, Raul O. de Lejarazu

We have read with great interest the work of Sandbulte et al. recently published in your journal [1]. In this article, the authors provide evidence for the existence of cross-immunity between the neuraminidase of H5N1 viruses and that of endemic human H1N1 viruses. Age may be an important determining factor in the development of cross-immunity: younger people, having a shorter history of H1N1 exposure, may be disproportionately susceptible to H5N1 infection.

We would like to highlight the influence of the geographic-dependent epidemiological behaviour of influenza in the development of cross-immunity. While Europe, the United States, and northern Asia experience regular outbreaks

of influenza each year, ("seasonal influenza"), influenza in tropical regions such as southern China, Vietnam, and Indonesia tends to be year-round ("non-seasonal" influenza). In consequence, the probability of exposure to influenza A in these regions persists throughout the entire year. Repetitive contacts with influenza wild viruses could promote the development of cross-immunity against different viral strains. Even more, it could represent a fortuitous mechanism for developed natural protection by the close and persistent exposure of the immune system to influenza wild viruses in regions known for being an important source of emergent viruses, like southern China.

Results from Sandbulte et al. show that antibodies play a dominant role in cross-protection. The authors underscore the possible benefit of seasonal influenza vaccination for human populations faced with the threat of pandemic H5N1 influenza. This idea deserves careful analysis. The main group at risk for severe complications of seasonal flu are people older than 65. In Western countries, this population is recommended to receive annual vaccinations. Generally speaking, elder vaccination rates in tropical countries are far lower than those in Western countries. Even with the low annual vaccination rate in elders, H5N1 infection is observed mostly in young people. The existence of sub-clinical or asymptomatic infections in elderly people cannot be ruled out, but the reason why there are no described clinical cases of H5N1 in people older than 40 years is currently unknown. An age-dependent differential distribution of avian-type receptors in the upper respiratory tract could be a possible explanation. On the other hand, Tumpey et al. [2] demonstrated that mucosal (but not parenteral) challenges with inactivated or live H3N2 virus protect against H5N1 infection in mice. These results could have a relevant consequence: does contact with circulating influenza A via the respiratory tract confer a higher degree of cross-protection than parenteral exposure to vaccines?

In conclusion, the non-seasonal epidemiological behaviour of influenza in tropical countries could dramatically influence the development of naturally induced cross-immunity against different influenza strains and diminish the risk of severe disease from new emergent strains in elderly people living in these countries. The apparent lack of H5N1 cases in the elderly may be the result of continued exposure to circulating non-seasonal influenza A via mucosal epithelium in the respiratory tract. Vaccination via the mucosal route could be a more efficient way to provide cross-protection against future pandemic strains than vaccination via the parenteral route. In this hypothetical scenario, Western countries would be under-protected. ■

Jesus F. Bermejo-Martin (bermejo@ped.uva.es)

Eduardo Arranz

Raul O. de Lejarazu
University of Valladolid
Valladolid, Spain

David J. Kelvin
Joint Influenza Research Center, Division of Immunology
Shantou University Medical College
Shantou, People's Republic of China
Division of Experimental Therapeutics
Toronto General Research Institute, University Health Network
Toronto, Ontario, Canada

Yi Guan

Honglin Chen

University of Hong Kong
Hong Kong, People's Republic of China

Pilar Perez-Breña

Inmaculada Casas

National Centre of Microbiology
Majadahonda, Spain

References

1. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, et al. (2007) Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. *PLoS Med* 4: e59. doi:10.1371/journal.pmed.0040059
2. Tumpey TM, Renshaw M, Clements JD, Katz JM (2001) Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. *J Virol* 75: 5141–5150.

Citation: Bermejo-Martin JF, Kelvin DJ, Guan Y, Chen H, Perez-Breña P, et al. (2007) Neuraminidase Antibodies and H5N1: Geographic-dependent influenza epidemiology could determine cross-protection against emerging strains. *PLoS Med* 4(6): e212. doi:10.1371/journal.pmed.0040212

Copyright: © 2007 Bermejo-Martin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: JFBM is supported by the Fondo de Investigaciones Sanitarias, Ministry of Health, Spain.

Competing Interests: The authors have declared that no competing interests exist.

Lethal Injection: Let's Be Honest about the Death Penalty

Lawrence Bonchek

I don't favor the death penalty, and I don't participate in executions, but I recognize that honorable people can disagree about the subject, and I don't consider physicians who wish to do so—to assure that death comes quickly and without unusual pain—to be behaving unethically. They could be seen as serving the interests of both the condemned and society.

The conundrum about lethal injection persists only because long-standing American Medical Association guidelines prohibit physicians from carrying out actual executions, or even pronouncing death, though they may certify it—a distinction without a difference. The lack of physician involvement has resulted in execution protocols based on outmoded pharmacologic methods, carried out by inconsistently qualified technicians, with results that are sometimes ineffective and therefore are understandably controversial.

Any qualified anesthesiologist could propose more reliable techniques. It is unreasonable to assert that a condemned person cannot be executed painlessly, when tens of thousands of people are anesthetized every single day for surgery with modern fast-acting anesthetic drugs (propofol, in particular) that are far more suitable than the outmoded execution drug thiopental. Induction of surgical anesthesia does occasionally cause slight injection pain, so how then can it be “cruel and unusual” to use the same drug and method for the initial step in executions? Next, potassium cannot fail to stop the heart instantly and insensibly if given in substantial amounts.

The debate about the death penalty should be conducted

about its morality, not about its methods, because the latter is merely a surrogate for serious debate. Opponents of the death penalty (like me) should recognize that it is unwise to criticize methods alone, because improved methods vitiate those arguments [1]. ■

Lawrence Bonchek (lbonchek@yahoo.com)

Lancaster General Hospital
Lancaster, Pennsylvania, United States of America

References

1. The *PLoS Medicine* Editors (2007) Lethal injection is not humane. *PLoS Med* 4: e171. doi:10.1371/journal.pmed.0040171

Citation: Bonchek L (2007) Lethal Injection: Let's be honest about the death penalty. *PLoS Med* 4(6): e213. doi:10.1371/journal.pmed.0040213

Copyright: © 2007 Lawrence Bonchek. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The author received no specific funding for this article.

Competing Interests: The author has declared that no competing interests exist.

Lethal Injection: Other Views

The *PLoS Medicine* Editors

The recently published research article on lethal injection [1] and our editorial commentary [2] both produced a number of short letters via our electronic reader response system.

There were five letters commenting on the research article. All were written by strong supporters of the death penalty who took the view that, as the victims of those who had been convicted of murder had suffered, the perpetrators should themselves experience pain as well as execution. We posted two of these letters on our Web site, but felt the other three were written in terms that made them unsuitable for inclusion.

Our editorial attracted 11 letters. Three supported the views we had expressed, one commented on a small factual error, and seven were hostile, again focusing on the desirability of making murderers suffer. We felt that one of the supportive letters (above) was of particular interest and we have therefore chosen to highlight it by means of formal publication in the Correspondence section of the journal. Of the seven hostile letters, we considered that four were suitable for posting on the Web site.

We do not intend, within our Correspondence section, to publish further letters commenting on the research article or the editorial. However, as with all the articles we publish, reader responses for the Web site may be submitted at any time. After a very brief screening for suitability, reader responses appear on the site within a day or two of submission. ■

The *PLoS Medicine* Editors

The Public Library of Science
San Francisco, California, United States of America

References

1. Zimmers TA, Sheldon J, Lubarsky DA, López-Muñoz F, Waterman L, et al. (2007) Lethal injection for execution: Chemical asphyxiation? *PLoS Med* 4: e156. doi:10.1371/journal.pmed.0040156
2. The *PLoS Medicine* Editors (2007) Lethal injection is not humane. *PLoS Med* 4: e171. doi:10.1371/journal.pmed.0040171

Citation: The *PLoS Medicine* Editors (2007) Lethal Injection: Other views. *PLoS Med* 4(6): e224. doi:10.1371/journal.pmed.0040224

Consent for Genomic Epidemiology in Developing Countries: Added Human Subject Protection Also Needed

Robert Reinhard

The authors deserve thanks for laying out decent principles of communication [1]. But serviceable consent language is insufficient to address all issues of protection. That was the point of recent workshops held by the National Institutes of Health to develop a genome-wide association studies program [2].

Risks associated with personal identification may be incurred if information is subject to code breaking. Legal means are available to compel identification, including across national boundaries. Privacy protections under the Health Insurance Portability and Accountability Act (HIPAA) are subject to exceptions, including for law enforcement, downstream data users, or for other reasons, and are not available internationally. Even with authorization, the complexities associated with a repository may frustrate attempts to achieve meaningful comprehension. Use of data for purposes other than pharmaceutical product development or biomedical interventions would be an abuse resulting perhaps in travel restrictions or discrimination.

For these reasons, safeguards should be added, including:

- Amendments to prevent non-medical health access to personal identification information;
- Restrictions on recruitment of populations especially vulnerable to disclosure risks, such as prisoners or immigrants;
- Prohibitions on disclosure to or use by employers or third-party payors to deny medical coverage, assign differential premium risks, restrict access to therapies, or unfairly discriminate in employment.

Another risk from creation of a genomics repository is the potential for unjust stigmatization (see for example [3]). A workable program would state that the data are appropriate only for limited public health purposes involving product development or professionally derived biomedical intervention, and are insupportable for other use or by political or non-medical entities.

A researcher publishing results based on the genomic data should state affirmatively a boilerplate recognition of the abuse potential for stigmatization. This mechanism could prevent others from the wayward misappropriation of data for purposes other than those intended by professionals. The boilerplate could read:

“Conclusions derived from the genotypic or phenotypic characterization of individuals, groups, or families in this [publication] are meaningful or supportable only for the purpose of biomedical intervention or treatment and are unethical, insupportable, or inappropriate for use in other purposes. Use of the data to support any result of

stigmatization, discrimination, or adverse social harm would constitute a misuse or abuse of the data.”

To increase the connection of benefits to participants, individuals should be given personal opportunities to receive news reports if they wish and learn of particular clinical trials directed at their characteristics. If the data are to be used in the development of pharmaceutical products, users should also be directed to plan and explain early on how targeted populations may have reasonable access to treatment or therapy if the product is successfully brought to market. These suggestions are consistent with the program outlined by Senator Barack Obama in the Genomics and Personalized Medicine Act of 2006 and Senator Olympia Snowe in the Genetic Information Nondiscrimination Act of 2007 [4,5].

Improved consent: Yes, but linked to and inseparable from strong protections and added benefits for participants. ■

Robert Reinhard (rreinhard@mofo.com)

San Francisco Vaccine Trials Unit
San Francisco, California, United States of America

References

1. Chokshi DA, Thera MA, Parker M, Diakite M, Makani J, et al. (2007) Valid consent for genomic epidemiology in developing countries. *PLoS Med* 4: e95. doi:10.1371/journal.pmed.0040095
2. National Institutes of Health (2006) Request for information (RFI): Proposed policy for sharing of data obtained in NIH supported or conducted genome-wide association studies (GWAS). Available: <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-094.html>. Accessed 24 May 2007.
3. Council for International Organizations of Medical Sciences (2006) Special ethical considerations for epidemiological research.
4. US Congress (2006) The Genomics and Personalized Medicine Act of 2006. S. 3822, 109th Congress, 2d session. Available: <http://www.govtrack.us/congress/billtext.xpd?bill=s109-3822>. Accessed 24 May 2007.
5. US Congress (2007) Genetic Information Nondiscrimination Act of 2007. S. 358, 110th Congress, 1st Session. Available: <http://www.govtrack.us/congress/bill.xpd?bill=s110-358>. Accessed 24 May 2007.

Citation: Reinhard R (2007) Consent for Genomic Epidemiology in Developing Countries: Added human subject protection also needed. *PLoS Med* 4(6): e214. doi:10.1371/journal.pmed.0040214

Copyright: © 2007 Robert Reinhard. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The author received no specific funding for this article.

Competing Interests: The author has declared that no competing interests exist.

Why Most Published Research Findings Are False: Author's Reply to Goodman and Greenland

John P. A. Ioannidis

I thank Goodman and Greenland for their interesting comments [1] on my article [2]. Our methods and results are practically identical. However, some of my arguments are misrepresented:

1. I did not “claim that no study or combination of studies can ever provide convincing evidence.” In the illustrative examples (Table 4), there is a wide credibility gradient (0.1% to 85%) for different research designs and settings.

2. I did not assume that all significant p -values are around 0.05. Tables 1–3 and the respective positive predictive value (PPV) equations can use any p -value (alpha). Nevertheless, the $p = 0.05$ threshold is unfortunately entrenched in many scientific fields. Almost half of the “positive” findings in

recent observational studies have p -values of 0.01–0.05 [3,4]; most “positive” trials and meta-analyses also have modest p -values.

3. I provided equations for calculating the credibility of research findings with or without bias. Even without any bias, PPV probably remains below 0.50 for most non-randomized, non-large-scale circumstances. Large trials and meta-analyses represent a minority of the literature.

4. Figure 1 shows that bias can indeed make a difference. The proposed modeling has an additional useful feature: As type I and II errors decrease, $PPV(\max) = 1 - [u/(R + u)]$, meaning that to allow a research finding to become more than 50% credible, we must first reduce bias at least below the pre-study odds of truth (u less than R). Numerous studies demonstrate the strong presence of bias across research designs: indicative reference lists appear in [5–7]. We should understand bias and minimize it, not ignore it.

5. “Hot fields”: Table 3 and Figure 2 present “the probability that at least one study, among several done on the same question, claims a statistically significant research finding.” They are not erroneous. Fields with many furtive competing teams may espouse significance-chasing behaviors, selectively highlighting “positive” results. Conversely, having many teams with transparent availability of all results and integration of data across teams leads to genuine progress. We need replication, not just discovery [5].

6. The claim by two leading Bayesian methodologists that a Bayesian approach is somewhat circular and questionable contradicts Greenland’s own writings: “One misconception (of many) about Bayesian analyses is that prior distributions introduce assumptions that are more questionable than assumptions made by frequentist methods” [8].

7. Empirical data on the refutation rates for various research designs agree with the estimates obtained in the proposed modeling [9], not with estimates ignoring bias. Additional empirical research on these fronts would be very useful.

Scientific investigation is the noblest pursuit. I think we can improve the respect of the public for researchers by showing how difficult success is. Confidence in the research enterprise is probably undermined primarily when we claim that discoveries are more certain than they really are, and then the public, scientists, and patients suffer the painful refutations. ■

John P. A. Ioannidis (jioannid@cc.uoi.gr)

University of Ioannina School of Medicine
Ioannina, Epirus, Greece

References

1. Goodman S, Greenland S (2007) Why most published research findings are false: Problems in the analysis. *PLoS Med* 4: e168. doi:10.1371/journal.pmed.0040168
2. Ioannidis JPA (2005) Why most published research findings are false. *PLoS Med* 2: e124. doi:10.1371/journal.pmed.0020124
3. Pocock SJ, Collier TJ, Dandreo KJ, de Stavola BL, Goldman MB, et al. (2004) Issues in the reporting of epidemiological studies: A survey of recent practice. *BMJ* 329: 883.
4. Kavvoura FK, Liberopoulos G, Ioannidis JP (2007) Selection in reported epidemiological risks: An empirical assessment. *PLoS Med* 4: e79. doi:10.1371/journal.pmed.0040079
5. Ioannidis JP (2006) Evolution and translation of research findings: From bench to where? *PLoS Clin Trials* 1: e36. doi:10.1371/journal.pctr.0010036
6. Gluud LL (2006) Bias in clinical intervention research. *Am J Epidemiol* 163: 493–501.
7. The Cochrane Collaboration (2007) Cochrane methodology register. Available: http://www3.cochrane.org/access_data/cmr/accessDB_cmr.asp. Accessed 23 May 2007.
8. Greenland S (2006) Bayesian perspectives for epidemiological research: I. Foundations and basic methods. *Int J Epidemiol* 35: 765–775.

9. Ioannidis JP (2005) Contradicted and initially stronger effects in highly cited clinical research. *JAMA* 294: 218–228.

Citation: Ioannidis JPA (2007) Why Most Published Research Findings Are False: Author’s reply to Goodman and Greenland. *PLoS Med* 4(6): e215. doi:10.1371/journal.pmed.0040215

Copyright: © 2007 John P. A. Ioannidis. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The author received no specific funding for this article.

Competing Interests: The author has declared that no competing interests exist.

Biomedical Journals and Global Poverty: Is HINARI a Step Backwards?

Javier Villafuerte-Gálvez, Walter H. Curioso, Oscar Gayoso

Much has been written about how open access to biomedical journals is vital for researchers in developing countries [1], but so much more needs to be done.

Our experience in Peru with the Health InterNetwork Access to Research Initiative (HINARI), an initiative managed by the World Health Organization that helps promote access to scientific information by providing free (or low cost) online access to major science journals, is not as accessible as hoped for and, in fact, is getting worse. When HINARI launched in 2003, it provided access to more than 2,300 major journals in biomedical and related social sciences [2].

In April 2007, we conducted a review of the first 150 science journals available through HINARI with the highest impact factors on the Science Citation Index [3]. We excluded open-access journals and journals that make online access free to low-income countries (e.g., *The New England Journal of Medicine*, British Medical Journal Publishing Group). We could not access any of the top five journals from major publishers such as Nature and Elsevier-Science Direct. In other words, from the Nature Publishing Group we had no access to *Nature Reviews Cancer*, *Nature Reviews Immunology*, *Nature Reviews Molecular Cell Biology*, *Nature*, or *Nature Medicine*, and from Elsevier ScienceDirect we had no access to *Cell*, *Cancer Cell*, *Current Opinion in Cell Biology*, *Immunity*, or *Molecular Cell*. In addition, we could not access any of the first-level journals from Blackwell, Oxford Press University, Lippincott Williams and Wilkins, or Wiley and Sons. In 2003, all these journals were available.

Our findings support comments received from users over the last 8–10 months at the main library at Universidad Peruana Cayetano Heredia (Oscar Gayoso, personal communication). Students and faculty could not get access to biomedical journals from Nature, Elsevier-Science Direct, Blackwell, Oxford Press University, Springer Science, Lippincott Williams and Wilkins, or Wiley and Sons through HINARI. The collections of journals from the above-mentioned publishers together represent approximately 57% (2,118 of 3,741) of journals that were supposed to be accessible through HINARI, while the remaining 43% accessible were largely composed of open-access journals or journals that make online access free to low-income countries.

Moreover, we have found a significant decrease in the number of users accessing HINARI at our institution. For example, the number of HINARI users has decreased from

12,144 in April 2005 to 5,655 in April 2007, which may reflect the loss of impact of the HINARI initiative at our institution. In contrast, the number of users accessing other databases such as ProQuest and EBSCO has increased over the last few months.

Our findings suggest that we not only have access to a reduced number of biomedical journals on HINARI, but we also have no access to the biomedical journals that have the highest impact factors. The HINARI Web site states that it is still incorporating new journal collections. However, we are afraid that any addition that will not provide access to major publishers (such as the Nature Publishing Group, Elsevier ScienceDirect, or Lippincott Williams and Wilkins) could lack real impact according to HINARI's goals.

Since 2003, Peruvian medical students and health professionals have substantially benefited from access to high-quality scientific information through HINARI. Few medical students and very few researchers in the developing world can pay the usual fee of US\$20–US\$45 to download one article. Not even some private universities in Peru can afford the minimum journal subscription rates, even though these subscriptions would help the universities to become less isolated from global medical research. Having to pay US\$1,000 per year to HINARI has left many public universities in the provinces of Peru without access because they cannot afford it. Even for the Peruvian institutions that are currently paying US\$1,000 per year to HINARI, what is the real benefit of their HINARI subscription now?

We fear that the loss of access to many key journals that are published by the major companies could be a major setback to the education of medical students in Peru and perhaps around the world. Furthermore, it could make biomedical research in developing countries like Peru, a key element in fighting poverty, even scarcer.

In conclusion, students and researchers in developing countries such as Peru, working at the frontlines of global health problems, need to access more biomedical journals

in order to practice evidence-based health care and conduct high-quality research. The recent loss of access to many key biomedical journals in Peru could be a step backwards. We hope the situation described in this letter might help lend support to the proposal of Godlee et al., who suggested that the World Health Organization and its partners should take the lead in establishing an international collaborative group along the lines of the Global Fund to fight AIDS, Tuberculosis and Malaria to achieve the goal of “Universal access to essential health-care information by 2015” or “Health information for all” [4]. ■

Javier Villafuerte-Gálvez

Walter H. Curioso (wcurioso@u.washington.edu)

Oscar Gayoso

Universidad Peruana Cayetano Heredia
Lima, Peru

References

1. The *PLoS Medicine* Editors (2006) How can biomedical journals help to tackle global poverty? *PLoS Med* 3: e380. doi:10.1371/journal.pmed.0030380
2. Aronson B (2002) WHO's Health InterNetwork Access to Research Initiative (HINARI). *Health Info Libr J* 19: 164–165.
3. Warschawski DR (2005) Journal impact factors. Available: <http://www.ibpc.fr/~dror/jif.html>. Accessed 23 May 2007.
4. Godlee F, Pakenham-Walsh N, Ncayiyana D, Cohen B, Packer A (2004) Can we achieve health information for all by 2015? *Lancet* 364: 295–300.

Citation: Villafuerte-Gálvez J, Curioso WH, Gayoso O (2007) Biomedical Journals and Global Poverty: Is HINARI a step backwards? *PLoS Med* 4(6): e220. doi:10.1371/journal.pmed.0040220

Copyright: © 2007 Villafuerte-Gálvez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Preparation of this article was supported in part by a grant from the Fogarty International Center, United States National Institutes of Health (5D43TW007551).

Competing Interests: The authors have declared that no competing interests exist.